Drosia BioPharma
Drosia BioPharma is advancing a novel dermal delivery platform designed to bring targeted biologic therapy directly to the site of chronic inflammatory skin disease. The platform is engineered to deliver large molecules through the skin barrier, concentrating treatment where it is needed while minimizing systemic exposure and associated side effects. The company's flagship program is progressing toward clinical development with a focus on patient comfort and practical usability.
- Healthcare Technology
- Biotechnology
- Drug Discovery & Therapeutics
Funding
Founders
Founder details are not available yet.
Product
Problem
Chronic inflammatory skin diseases are often treated with systemic biologics that can cause broad immunosuppression and off-target effects, while topical formulations struggle to deliver large molecules effectively through the skin barrier. This leaves patients with limited options that either lack efficacy or come with significant side effects.
Solution
Drosia BioPharma is advancing a novel dermal delivery platform engineered to place biologic therapy precisely where it is needed in the skin, targeting the underlying drivers of chronic inflammatory conditions rather than just surface symptoms. The platform is designed to deliver large molecules directly to the disease site, potentially improving efficacy while minimizing systemic exposure and associated side effects. The company's flagship program is progressing toward clinical development, with a focus on patient comfort and practical usability. By combining precision delivery with targeted biology, Drosia aims to unlock meaningful new treatment options for patients with inflammatory skin disease.
Target Audience
Primary customers are patients with chronic inflammatory skin conditions who need more effective, targeted treatment options, as well as dermatology and immunology specialists seeking biologic therapies with improved local delivery and reduced systemic side effects.
Features
- Dermal delivery platform specifically engineered for biologic therapeutics, addressing the challenge of delivering large molecules through the skin
- Targeted delivery to the disease site, designed to concentrate therapy where it is needed and reduce systemic exposure
- Focus on the underlying drivers of chronic inflammatory skin conditions, not just symptomatic relief
- Patient-comfort-oriented formulation approach intended to support practical, real-world use
- Flagship program advancing toward the clinic with support from expert clinical, regulatory, and IP advisers